Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.55 HKD | +0.92% |
|
+2.02% | -12.90% |
Jun. 25 | 3Sbio Inc. Declares Final Dividend for the Year Ended 31 December 2023, Payable on 5 August 2024 | CI |
Jun. 25 | 3Sbio Inc. Announces Board Changes | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is in a robust financial situation considering its net cash and margin position.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.90% | 1.96B | B | ||
+4.74% | 40.94B | A- | ||
-11.48% | 33.35B | B- | ||
+81.81% | 29.53B | A | ||
-13.94% | 15.76B | C | ||
-3.33% | 13.65B | B- | ||
-12.64% | 11.44B | D+ | ||
+166.50% | 10.08B | D | ||
+5.32% | 9.06B | B+ | ||
-57.32% | 8.58B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1530 Stock
- Ratings 3SBio Inc.